Ranbaxy Deal Could Make Investors Shy About Indian Pharmas
This article was originally published in PharmAsia News
Executive Summary
The pending sale of India's Ranbaxy Laboratories to Japan's Daiichi Sankyo is leading private equity firms to take a second look at investing in Indian drug makers. The firms see the Daiichi move as illustrating the vulnerability of India's pharma industry. One response could be setting more preconditions before making an investment to keep a company from selling soon after the equity firms provide an infusion of funds. In light of the Daiichi-Ranbaxy deal, investors are likely to see the pharmaceutical industry in India as more acquisition-prone than some other industries. (Click here for more